Core Viewpoint - Bayer's launch of Aflibercept 8mg during the China International Import Expo aims to address the increasing burden of neovascular age-related macular degeneration (nAMD) and improve patient compliance and quality of life [1][2]. Group 1: Product Launch and Approval - Aflibercept 8mg was approved by the National Medical Products Administration in May 2023 for the treatment of nAMD [1]. - The product features a longer treatment interval, which is expected to enhance patient adherence to treatment [1]. Group 2: Disease Background and Treatment Gaps - nAMD is characterized by abnormal growth and leakage of new blood vessels in the macula, leading to irreversible vision loss in the elderly [1]. - Current treatment methods, primarily anti-VEGF injections, show significant gaps in disease control and require frequent administration, which affects long-term treatment adherence [1]. Group 3: Product Advantages - Aflibercept is a fully humanized fusion protein that offers broader inhibition of the VEGF family compared to monoclonal antibodies [2]. - The higher concentration of Aflibercept 8mg allows for a greater number of molecules to be injected at once, resulting in more effective and durable VEGF inhibition [2]. - The upgrade to Aflibercept 8mg provides stronger early efficacy and more durable disease control, offering clinicians and patients more flexible treatment options [2].